1373754-96-1

Upstream product

• 1361567-63-6 C₁₃H₈Cl₃NO₂ 
• 365413-19-0 6-hydroxy-5-iodonicotinic acid 
• 365413-29-2 6-chloro-5-iodonicotinic acid methyl ester 
• 885950-46-9 6-hydroxy-5-iodonicotinic acid methyl ester 
• 75-89-8 2,2,2-trifluoroethanol 
• 1361748-71-1 6-chloro-5-(3,4-dichloro-phenyl)-nicotinic acid 
• 66171-50-4 methyl 6-hydroxynicotinate 
• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 

Downstream Products

• 1382465-25-9 N-{2-cyclopropyl-2-[(E)-methoxyimino]-ethyl}-5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide 
• 1382465-53-3 N-(2-cyclopropyl-2-oxo-ethyl)-5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide 
• 1382465-57-7 {[5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-pyridine-3-carbonyl]-amino}-acetic acid tert-butyl ester 
• 1382465-67-9 N-{2-cyclopropyl-2-[(Z)-2,2,2-trifluoro-ethoxyimino]-ethyl}-5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide 
• 1382465-35-1 N-{2-cyclopropyl-2-[(E)-2,2,2-trifluoro-ethoxyimino]-ethyl}-5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide 
• 1382465-24-8 N-(E)-(2-cyclopropyl-2-hydroxyimino-ethyl)-5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide 
• 1382465-56-6 {[5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-pyridine-3-carbonyl]-amino}-acetic acid 
• 1382465-55-5 2-[5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-pyridin-3-yl]-4-(2,2,2-trifluoro-acetyl)-4H-oxazol-5-one 
• 1382465-54-4 5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-N-(3,3,3-trifluoro-2-oxo-propyl)-nicotinamide 
• 1382465-28-2 5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-N-{3,3,3-trifluoro-2-[(Z)-methoxyimino]-propyl}-nicotinamide 

Relevant academic research and scientific papers

OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS

The present invention relates to compounds of the formula (I) wherein A1 to A3 and R1 to R9 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

OXIME COMPOUNDS

The present invention relates to compounds of the formula wherein A1 to A3 and R1 to R9 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

PROCESS FOR THE PREPARATION OF NICOTINAMIDE DERIVATIVES

The present invention relates to a process for the preparation of nicotinamide derivatives of formula I, wherein R1 to R7 are as defined above and to pharmaceutically acceptable salts thereof. The compounds of formula I are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of cannabinoid 1 receptors (CB1 receptors) as described in the PCT Publ. WO 2006/106054.

PROCESS FOR THE PREPARATION OF NICOTINAMIDE DERIVATIVES

The present invention relates to a process for the preparation of nicotinamide derivatives of the formula (I) R1 to R7 are as defined in the and to pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful for the treatment and / or prophylaxis of diseases which are associated with the modulation of cannabinoid 1 receptors (CB 1 receptors) as described in the PCT Publ. WO 2006/106054.